scholarly journals Perineural invasion as a prognostic risk factor in patients with early cervical cancer

2018 ◽  
Author(s):  
Mei Tang ◽  
Qiuli Liu ◽  
Xueqing Yang ◽  
Ling Chen ◽  
Jinjin Yu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Risk Factor ◽  
Perineural Invasion ◽  
Early Cervical Cancer

scholarly journals Perineural Invasion Should Be Regarded as an Intermediate-Risk Factor for Recurrence in Surgically Treated Cervical Cancer: A Propensity Score Matching Study

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Ting Wan ◽  
Hua Tu ◽  
Lili Liu ◽  
He Huang ◽  
Yanling Feng ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Overall Survival ◽  
Risk Factor ◽  
High Risk ◽  
Propensity Score ◽  
Cancer Patients ◽  
Perineural Invasion ◽  
Intermediate Risk ◽  
High Risk Factors

Background. Perineural invasion (PNI) is considered as a poor prognostic factor in cervical cancer, but there has been no postoperative adjuvant therapy for it, because whether it belongs to high- or intermediate-risk factors has not been determined, this study intends to provide evidences to solve this problem. Methods. We conducted a retrospective analysis of cervical cancer patients who underwent radical surgery and be reported PNI from January 2012 to June 2017 at the Sun Yat-sen University Cancer Center. After 1 : 1 propensity score matching (PSM), a group of patients without PNI was matched according to the clinical pathological features. Postoperative pathological parameters and prognosis were evaluated between the PNI and the matched groups. Results. 1836 patients were screened, of which 162 (8.8%) diagnosed as stages IB1 to IIB reported PNI. Comparing to the matched group, more PNI (+) patients had deep outer cervix stromal invasion, cervical tunica adventitia invasion, positive lymph nodes, and positive margins. Among patients without high-risk factors, PNI (+) patients had worse 3-year overall survival (90.8% vs. 98.1%, P = 0.02 ), PNI (+) patients with single intermediate-risk factor and PNI (-) patients who meet with SEDLIS criteria had similar progress free survival ( P = 0.63 ) and overall survival ( P = 0.63 ), even similar survival curves. Conclusion. PNI is related to a worse overall survival among cervical cancer patients without high-risk factors and play the role as an intermediate-risk factor.

Transrectal ultrasound (TRUS) and MRI in staging of early cervical cancer

2007 ◽  
Vol 28 (S 1) ◽  
Author(s):  
D Fischerova ◽  
D Cibula ◽  
M Zikan ◽  
P Calda ◽  
H Vondrichova ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Transrectal Ultrasound ◽  
Early Cervical Cancer

Efficiency of diagnosis and treatment non-invasive and microinvasive sgamous cell cervical cancer

2020 ◽  
pp. 71-74
Author(s):  
M.M. Melnyk ◽  
◽  
S.V. Nespradko ◽  
I.V. Goncharuk ◽  
M.V. Marchenko ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Key Words ◽  
National Cancer Institute ◽  
Reproductive Function ◽  
Diagnosis And Treatment ◽  
Non Invasive ◽  
Corpus Uteri ◽  
Complex Program ◽  
Early Cervical Cancer

The objective: analyse the effectiveness of diagnosis and treatment for early cervical cancer. Materials and methods. Analysed 107 cases of women’s disease on CIN ІІІ, cancer in situ, they were on treatment in National cancer institute and Kyiv dictrict cancer dispensary from 2010 till 2015 years. Results. Diagnosed percent relapse CIN ІІІ, cancer in situ contain 4.57% uninvasive and invasive form – 0.94%. Conclusion. According diagnostic CIN ІІ and CIN ІІІ is recommended to do treatment conization and dynamic dispensary observation. Are making complex program of infection HPV16, 18. In appering of margins resection some elements of tumor after wider conization by forms of cancer in situ. Many of expansive burns in cervical glands, in making of reproductive function, going disease (nodel leiomyoma of corpus uteri etc). In perspective is accept the notion of looking after and screening research of considering infection HPV16, 18 on CIN І, CIN ІІ. Key words: cervical cancer, сancer in situ, CIN І–ІІІ, diagnostic, treatment, conization.

scholarly journals From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 597
Author(s):  
Daniela Luvero ◽  
Salvatore Lopez ◽  
Giorgio Bogani ◽  
Francesco Raspagliesi ◽  
Roberto Angioli
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Risk Factor ◽  
Hpv Vaccine ◽  
Global Market ◽  
Cancer Death ◽  
Prevention Measures ◽  
Primary And Secondary Prevention ◽  
The World ◽  
Prevention And Treatment

Cervical cancer (CC) is the second leading cause of cancer death in women aged 20–39 years. Persistent infection with oncogenic types of human papillomavirus (HPV) represents the most important risk factor for the development of cervical cancer. Three HPVs vaccines are currently on the global market: bivalent, quadrivalent, and nonavalent. The nonavalent vaccine provides protection against almost 90% of HPV-related CC. Despite availability of primary and secondary prevention measures, CC persists as one of the most common cancers among women around the world. Although CC is a largely preventable disease, management of persistent or recurrent CC no longer amenable to control with surgery or radiation therapy has not improved significantly with the progress of modern chemotherapy and disseminated carcinoma of the cervix remains a discouraging clinical entity with a 1-year survival rate between 10% and 15%. Over the last few years, there has been increasing interest in immunotherapy as a strategy to fight tumors. This article focuses on recent discoveries about the HPV vaccine and immunotherapies in the prevention and treatment of CC, highlighting the future view.

Sign in / Sign up

Export Citation Format

Share Document